A phase 0 first-in-human study using NU-0129: A gold base spherical nucleic acid (SNA) nanoconjugate targeting BCL2L12 in recurrent glioblastoma patients.

Priya Kumthekar,Alfred W. Rademaker,Caroline H. Ko,Karan Dixit,Margaret Schwartz,Adam M. Sonabend,Laura Sharp,Rimas V. Lukas,Roger Stupp,Craig Horbinski,Kathleen McCortney,Alexander H. Stegh

A phase 0 first-in-human study using NU-0129: A gold base spherical nucleic acid (SNA) nanoconjugate targeting BCL2L12 in recurrent glioblastoma patients.

2019

Priya Kumthekar
Alfred W. Rademaker
Caroline H. Ko
Karan Dixit
Margaret Schwartz
Adam M. Sonabend
Laura Sharp
Rimas V. Lukas
Roger Stupp
Craig Horbinski
Kathleen McCortney
Alexander H. Stegh

3012Background: Glioblastoma is a difficult to treat tumor with therapeutics limited by their ability to cross the blood brain barrier. SNAs, i.e., gold nanoparticle cores covalently conjugated wit...

Keywords:

Spherical nucleic acid
Human study
Glioblastoma
Pathology
Cancer research
Medicine
Conjugated system
first in human
Blood–brain barrier
recurrent glioblastoma

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations